The incidence and type of cancer in patients with ataxia‐telangiectasia via a retrospective single‐centre study

Shahrzad Bakhtiar, Emilia Salzmann‐Manrique, Helena Donath, Sandra Woelke, Ruth Pia Duecker, Stefanie Fritzemeyer, Ralf Schubert, Sabine Huenecke, Matthias Kieslich, Thomas Klingebiel,

British Journal of Haematology · 2021 · 35 citations · 24 references

DOIFull text

Open access

Concepts

TL;DR

Ataxia‑telangiectasia is a hereditary immune‑system disorder characterized by neurodegeneration, early‑onset cerebellar ataxia, oculomotor apraxia, telangiectasia, and muscle weakness, and can be identified by neonatal screening for severe T‑cell deficiency. The study emphasizes the necessity of cancer surveillance, prevention, and optimal treatment for patients with A‑T. The authors retrospectively reviewed 69 A‑T patients from 2002 to 2019. Among the 69 patients, 25% developed cancer, with a median overall survival of 26.9 years; those with malignancies had a median OS of 2.11 years and a 15‑fold higher risk of death from hematologic cancers, and males had a higher cancer risk than females.

Abstract

Ataxia-telangiectasia (A-T) is a hereditary immune system disorder with neurodegeneration. Its first neurologic symptoms include ataxic gait in early childhood, with slowly progressive cerebellar ataxia, oculomotor apraxia, oculocutaneous telangiectasia, and progressive muscle weakness. Neonatal screening for severe T-cell deficiency was recently found to diagnose A-T patients with a significantly reduced naïve T-cell pool. Our study includes 69 A-T patients between 8 January 2002 and 1 December 2019. Nineteen cases of cancer were diagnosed in 17 patients (25%), with a median overall survival [OS; 95% cumulative indcidence (CI)] of 26·9 years for the entire cohort. The 15-year OS of 82·5% (72-95%) was significantly decreased among A-T patients with malignancies, who had a median OS of 2·11 years, with a two-year-estimated OS of 50·7% (31-82%). Haematological malignancies were the major causes of death within the initial years of life with a 15 times increased risk for death [HR (95% CI): 6·9 (3·1-15.2), P < 0·001] upon malignancy diagnosis. Male patients with A-T are at a higher cancer risk than their female counterparts. This manuscript highlights the need for cancer surveillance and prevention, as well as optimal treatment in this cohort.

References

24